Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Trametinib as a promising therapeutic option in alleviating vascular defects in an endothelial KRAS-induced mouse model.

Human molecular genetics - 6 Jan 2023

Nguyen Ha-Long, Boon Laurence M, Vikkula Miikka

Abstract excerpt

Somatic activating Kirsten rat sarcoma viral oncogene homologue (KRAS) mutations have been reported in patients with arteriovenous malformations. By producing LSL-Kras (G12D); Cdh5 (PAC)-CreERT2 [iEC-Kras (G12D*)] mice, we hoped to activate KRAS within vascular endothelial cells (ECs) to generate an arteriovenous malformation mouse model. Neonatal mice were treated daily with tamoxifen from postnatal (PN) days...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Models, Animal
Share to Endothelial Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 35972810
DOI: 10.1093/hmg/ddac169

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Trametinib as a promising therapeutic option in alleviating vascular defects in an endothelial KRAS-induced mouse model.PMID 35972810Read ↗

Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling.Semantic proximity Read ↗

CRISPR/CasRx suppresses KRAS-induced brain arteriovenous malformation developed in postnatal brain endothelial cells in mice.Semantic proximity Read ↗

MEK signaling represents a viable therapeutic vulnerability of <i>KRAS</i> -driven somatic brain arteriovenous malformationsSemantic proximity Read ↗

Sotorasib for Vascular Malformations Associated with KRAS G12C Mutation.Semantic proximity Read ↗

Vascular malformations: An overview of their molecular pathways, detection of mutational profiles and subsequent targets for drug therapySemantic proximity Read ↗

KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2K-MAPK1 inhibition.Semantic proximity Read ↗

Advances in the Study of KRAS in Brain Arteriovenous Malformation.Semantic proximity Read ↗

Genetic Basis and Therapies for Vascular Anomalies.Semantic proximity Read ↗

Endothelial cell expression of mutant Map2k1 causes vascular malformations in mice.Semantic proximity Read ↗

Arteriovenous malformation Map2k1 mutation affects vasculogenesis.Semantic proximity Read ↗

Development of Molecular Therapies for Venous Malformations.Semantic proximity Read ↗

New and Emerging Targeted Therapies for Vascular Malformations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.